203 related articles for article (PubMed ID: 2771993)
21. Superficial bladder disease: case studies and therapeutic advances.
Soloway MS; Droller MJ; Flanigan RC; Nseyo UO
Urology; 1992 Dec; 40(6 Suppl):11-22. PubMed ID: 1466118
[No Abstract] [Full Text] [Related]
22. Intravesical instillation of BCG in carcinoma in situ of the urinary bladder. EORTC protocol 30861. EORTC-GU Group.
Jakse G
Prog Clin Biol Res; 1989; 310():187-92. PubMed ID: 2771992
[TBL] [Abstract][Full Text] [Related]
23. Adriamycin versus BCG in superficial bladder cancer: a Southwest Oncology Group Study.
Lamm DL; Crissmann J; Blumenstein B; Crawford ED; Montie J; Scardino P; Grossman HB; Stanisic T; Smith J; Sullivan J
Prog Clin Biol Res; 1989; 310():263-70. PubMed ID: 2672016
[No Abstract] [Full Text] [Related]
24. [Topical BCG therapy of in situ cancer of the urinary bladder].
Mack D; Jakse G
Urologe A; 1987 Jan; 26(1):22-5. PubMed ID: 3576860
[TBL] [Abstract][Full Text] [Related]
25. [Intravesical instillations of BCG and bladder carcinoma in situ].
Haab F; Dauge MC; Delmas V; Boccon-Gibod L
Prog Urol; 1993 Dec; 3(6):988-94; discussion 992-3. PubMed ID: 8305942
[TBL] [Abstract][Full Text] [Related]
26. Intravesical adjuvant treatment in superficial bladder cancer. A review of the question after 15 years of experience with the EORTC GU group.
Bouffioux C
Scand J Urol Nephrol Suppl; 1991; 138():167-77. PubMed ID: 1838428
[No Abstract] [Full Text] [Related]
27. Intravesical Bacillus Calmette Guerin therapy in patients with superficial bladder tumor.
Steg A; Belas M; Leleu C; Boccon-Gibod L
Prog Clin Biol Res; 1989; 303():375-81. PubMed ID: 2780654
[No Abstract] [Full Text] [Related]
28. [Prophylactic effects of zhuling and BCG on postoperative recurrence of bladder cancer].
Yang DA; Li SQ; Li XT
Zhonghua Wai Ke Za Zhi; 1994 Jul; 32(7):433-4. PubMed ID: 7842985
[TBL] [Abstract][Full Text] [Related]
29. In situ transitional cell carcinoma involvement of prostatic urethra: bacillus Calmette-Guérin therapy without previous transurethral resection of the prostate.
Palou J; Xavier B; Laguna P; Montlleó M; Vicente J
Urology; 1996 Apr; 47(4):482-4. PubMed ID: 8638354
[TBL] [Abstract][Full Text] [Related]
30. BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale and design of the trial of the Southeast Co-operative Urological Group, The Netherlands.
van der Meijden PM; Debruyne FM; Steerenberg PA; de Jong WH; Doesburg W
Prog Clin Biol Res; 1989; 310():285-98. PubMed ID: 2505272
[No Abstract] [Full Text] [Related]
31. [The preventive recurrent results of postoperative intravesical instillation therapy in bladder cancer].
Zhang S; Li H; Cheng H
Zhonghua Wai Ke Za Zhi; 1995 May; 33(5):304-6. PubMed ID: 7587700
[TBL] [Abstract][Full Text] [Related]
32. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
[TBL] [Abstract][Full Text] [Related]
33. Low-dose BCG-Pasteur strain in the treatment of superficial bladder cancer: preliminary results.
Pagano F; Bassi P; Milani C; Meneghini A; Tuccitto G; Garbeglio A; Guazzieri S
Prog Clin Biol Res; 1989; 310():253-61. PubMed ID: 2672015
[No Abstract] [Full Text] [Related]
34. [Intravesical BCG vaccine in bladder cancer].
Beisland HO; Sander S
Tidsskr Nor Laegeforen; 1989 Jun; 109(17-18):1891-2. PubMed ID: 2749672
[TBL] [Abstract][Full Text] [Related]
35. Multicenter study of the BCG Tokyo strain for intravesical treatment in patients with superficial bladder cancer. BCG Study Group.
Aso Y; Akaza H; Kameyama S; Niijima T
Prog Clin Biol Res; 1989; 303():383-91. PubMed ID: 2675000
[No Abstract] [Full Text] [Related]
36. Principles of intravesical chemotherapy and immunotherapy.
Sarosdy MF
Urol Clin North Am; 1992 Aug; 19(3):509-19. PubMed ID: 1636235
[TBL] [Abstract][Full Text] [Related]
37. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
de Reijke TM; de Boer EC; Kurth KH; Schamhart DH
J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
[TBL] [Abstract][Full Text] [Related]
38. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
[TBL] [Abstract][Full Text] [Related]
39. Pathologic and structural changes in the bladder after BCG intravesical therapy in men.
Pagano F; Bassi P; Milani C; Dalla Palma P; Rebuffi AG; Poletti A; Parenti A
Prog Clin Biol Res; 1989; 310():81-91. PubMed ID: 2771996
[No Abstract] [Full Text] [Related]
40. BCG in carcinoma in situ and superficial bladder tumors.
Lamm DL
Prog Clin Biol Res; 1988; 269():497-510. PubMed ID: 3293069
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]